| Literature DB >> 33437886 |
Craig A Obafemi1, Oluwaseun B Adegbite1, Olatomide A Fadare1, Ezekiel O Iwalewa2, Nusrat O Omisore3, Kayode Sanusi1, Yusuf Yilmaz4, Ümit Ceylan5.
Abstract
Tryptanthrin is a potent natural alkaloid with good in vitro pharmacological properties. Herein, we report the synthesis of the compound via a new method involving the reduction of isatin with solid-state-supported sodium borohydride under microwave irradiation. The title compound has been tested for its analgesic and anti-inflammatory activity. The results showed that tryptanthrin dose dependently inhibits oedema and pain formation in all the models used. The agent also exhibited significant higher effects in its anti-inflammatory and analgesic activities better than positive drugs (aspirin and indomethacin) being currently used in the treatment and in the management of acute and chronic forms of pain and inflammatory disorders. The inhibitory potential of the compound was investigated by molecular docking using the software AutoDock Vina. The docking results were used to better rationalize the action and prediction of the binding affinity of tryptanthrin. Density Functional Theory (DFT) calculations at the B3LYP/6-311++G (2df, 2pd) level of theory showed that compared to ascorbic acid, tryptanthrin shows higher antioxidant activity which may be improved upon by functionalizing the aromatic core to enhance its solubility in polar solvents. The calculated electronic and thermodynamic properties obtained for tryptanthrin compete well with the standard ascorbic acid.Entities:
Keywords: Analgesic and anti-inflammatory activity; Borohydride reduction; DFT calculations; Isatin; Molecular docking; Tryptanthrin
Year: 2020 PMID: 33437886 PMCID: PMC7788106 DOI: 10.1016/j.heliyon.2020.e05756
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Scheme 1Synthetic routes to tryptanthrin and its atom numbering.
Sodium borohydride reduction of isatin (6.8 mmol) under solvent-free microwave irradiation.
| Entry | Conditions | Time (min) | Products (% yield) | Rf value |
|---|---|---|---|---|
| 1 | SiO2 (10.0 g), NaBH4 (1.2 equiv) | 5 | NR | - |
| 2 | SiO2 (5.0 g), NaBH4 (2.3 equiv) | 5 | NR | - |
| 3 | SiO2 (5.0 g), NaBH4 (2.3 equiv) | 10 | 0.90, 0.82, ∗0.48 | |
| 4 | SiO2 (5.0 g), NaBH4 (2.3 equiv) | 20 | 0.88, 0.81, ∗0.45 | |
| 5 | Al2O3 (acidic) (5.0 g), NaBH4 (2.3 equiv) | 20 | NR | - |
| 6 | Al2O3 (basic) (10.0 g), NaBH4 (2.3 equiv) | 5 | NR | - |
| 7 | Al2O3 (basic) (10.0 g), NaBH4 (2.3 equiv) | 10 | 0.87, ∗0.44 | |
| 8 | MgSO4.7H2O (10.0 g), NaBH4 (2.3 equiv) | 10 | NR | - |
| 9 | MgSO4.7H2O (10.0 g), NaBH4 (2.3 equiv) | 30 | 0.88, 0.82, 0.75, ∗0.45 | |
| 10 | 5 | NR | - | |
| 11 | 20 | 0.88, ∗0.46 |
NR = No Reaction; ∗2 = unreacted isatin; P2, P3 = unidentified products; 2-N-COCH3 = 1-acetylisatin
Residues within 4 Å of the native S58 and comparison with interacting residues of the docked S58, celecoxib and tryptanthrin.
| Compounds | Residues within 4 Å of the docked compounds/bound inhibitor | Binding energy (-kcal/mol) | Polar contacts |
|---|---|---|---|
| 1CX2 with bound inhibitor (S58) | |||
| S58 | 11.2 | HIS90 (flex, 2.7A); ARG513 (flex, 2.6 & 2.2A); SER353 (2.1A) | |
| Celecoxib | 11.3 | HIS90 (flex, 2.6A); TYR355 (flex, 2.9A) | |
| Tryptanthrin | 9.7 |
The residues in bold font are those associating with the native S58 in the designated binding site that are also associating with the other compounds docked with the protein. The residues in italics are those aside from the ones interacting with the native ligand that are also interacting with the docked compounds. Almost all italicized residues for tryptanthrin indicate that the tryptanthrin must have bound to a different site in the protein.
Figure 1(a) Optimized structure of tryptanthrin (Ioxi) (b) Four-electron oxidized/reduced forms of catechol (II) (c)Reduced form of tryptanthrin (Ired)
Scheme 2Isodesmic redox-conversion of compound (I) by catechol (II).
Scheme 3Thermodynamic cycle employed to obtain compound I redox potential.
Calculated total free energy (ΔGT), redox potential (EM+/M) and electronic parameters of the studied compounds.
| ΔGT (kJ/mol) | EMoxi/Mred (mV) | IP ( | EA ( | |||||
|---|---|---|---|---|---|---|---|---|
| 1’ (Ioxi) | 478.50 | -1229.0 | 665.21 | 312.73 | 2.1074 | -665.21 | -312.73 | 352.47 |
| Ascorbic Acid | 284.90 | -727.40 (-0.281) | 1041.1 | 107.77 | 9.5490 | -1041.1 | -107.77 | 933.19 |
Ref. [84].
Ref. [83].
Scheme 4Isodesmic redox-conversion of ascorbic acid (AA) by catechol (II).
Scheme 5Sodium borohydride reduction of some substituted indole-2,3-dione (isatin) [57, 58].
Scheme 6Possible rationalization of sodium borohydride reduction of isatin to tryptanthrin
The effects of synthetic tryptanthrin agent on acute inflammation and pulmonary oedema induced inflammatory responses in mice.
| Compound | Doses (mg/kg) | Acute Inflammation | % Inhibition (AI) | Pulmonary Oedema | % inhibition (PO) |
|---|---|---|---|---|---|
| Negative control (DMSO) | 0.3 mL | 0.109 ± 0.006 | 0 | 83.3 ± 2.2 | 0 |
| Tryptanthrin | 6 | 0.048 ± 0.011∗ | 55.963 | 61.98 ± 10.78 | 25.59 |
| Indomethacin | 10 | 0.038 ± 0.005∗ | 65.137 | 60.0 ± 1.1 | 27.97 |
Values represent means ± SEM of 5 animals ∗p < 0.05.
The effects of synthetic tryptanthrin agent on tail immersion, hot plate (as thermal stimuli), and acetic acid induced writhing (as chemical stimulus) induced pain responses in mice.
| Compounds | Doses (mg/kg) | Tail immersion (sec) | Hot plate reaction (sec) | Acetic acid induced writhing |
|---|---|---|---|---|
| Negative control (DMSO) | 0.3 mL | 1.7 ± 0.30 | 8.9 ± 0.57 | 51.0 ± 6.08 |
| Tryptanthrin | 6 | 2.69 ± 0.78 | 11.38 ± 2.67∗ | 75.40 ± 9.85 |
| Acetysalicyclic acid | 100 | 4.5 ± 0.30∗ | 16.2 ± 2.90∗∗ | 19.6 ± 0.80∗∗ |
Values represent means ± SEM of 5 animals ∗p < 0.05, ∗∗p,0.01.
Figure 2(a) Cartoon rendering of the protein showing tryptanthrin overlapping with heme in the same site. (b) Cartoon rendering of the protein showing the flexible residues at the S58 binding site adjacent to the site where heme occupies in the protein. (c) A surface rendering of the protein showing tryptanthrin lodged in the pocket that seats the heme (without the heme). (d) Another surface rendering showing the tryptanthrin overlapped with the heme in the heme pocket.
Experimental and calculated 1H NMR data.
| Calculated | % Error | |
|---|---|---|
| 7.41 [1H, | 6.97 | 5.94 |
| 7.66 [1H, | 7.29 | 4.83 |
| 7.77 [1H, | 7.31 | 5.92 |
| 7.84 [1H, | 7.42 | 5.36 |
| 7.91 [1H, | 7.55 | 4.55 |
| 8.00 [1H, | 7.61 | 4.88 |
| 8.42 [1H, | 8.32 | 1.19 |
| 8.60 [1H, | 8.49 | 1.27 |
| 4.08 | ||
(Our lab.)
Reference shielding δ value calculated by HF/6-31G, TMS = 32.60 ppm, information in square brackets = proton quantity and multiplicities.
Wavenumbers (experiment and theory) and band assignments for compound Ioxi.
| Experimental | Calculated | Band assignments |
|---|---|---|
| 1727 | 1796 | υC = O (ketone) |
| 1685 | 1736 | υC = O (amide) |
| 1594 | 1631 | υC = C |
| 1314 | 1323 | |
| 1113 (w) | 1120 | |
| 1040 (w) | 1029 | |
| 755 | 777 | γC-H (Ar) |
Experimental data as obtained from our laboratory.
υ: stretching; γ: out-of-plane bending.
Figure 3Calculated electronic absorption spectrum of tryptanthrin
Figure 4Molecular orbital energy levels of tryptanthrin
Figure 5Molecular orbital symmetries corresponding to the different molecular energy levels of tryptanthrin